Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.
Karolinska Development's portfolio company Dilafor advances tafoxiparin following successful meetings with FDA and European regulatory authorities
Dilafor has completed interactions with US and European authorities during 2023 – 2024 to achieve an alignment in the regulatory process ahead of the upcoming clinical phase 3 trials with the ...
Pound Sterling drops against USD despite moderate US Q4 GDP growth
The Pound Sterling exhibits a sharp volatility contraction around 1.2450 against the US Dollar on Thursday. The near-term ...
PharmiWeb7h
Cardiac Pacemaker Market: Growth Drivers and Technological Advancements
The cardiac pacemaker market has witnessed significant growth over recent years, driven by the increasing prevalence of heart diseases, advancements in pacemaker technology, and growing awareness ...
EUR/USD, USD/JPY and AUD/USD Forecast – US Dollar Mixed Against Other Major Currencies
The US dollar is looking at the nonsense at the FOMC press conference from the previous session, as well as a cooler than expected Advanced GDP in the US.